Immunoglobulin News and Research

RSS

The immune system's role in hepatitis C recurrence after liver transplantation

A new study pinpoints certain aspects of the immune system that may play a role in the recurrence and progression of hepatitis C virus (HCV) after liver transplantation.

1 Apr 2009

Protein from tick saliva shows potential for myasthenia gravis treatment

Looking for a better treatment for the autoimmune disease myasthenia gravis, researchers have found that a protein in tick saliva shows promise in limiting the severity of the disease in an animal model in a study published in the Annals of Neurology.

29 Mar 2009

Children can complete treatment for peanut allergies and achieve long-term tolerance

A carefully administered daily dose of peanuts has been so successful as a therapy for peanut allergies that a select group of children is now off treatment and eating peanuts daily, report doctors at Duke University Medical Center and Arkansas Children's Hospital.

15 Mar 2009

Number of cardiovascular risk factors could determine safety of IVIg treatment

New research out of Wake Forest University School of Medicine identifies the presence of cardiovascular risk factors as an indicator of how likely it is that elderly, hospitalized patients who receive intravenous immunoglobulin (IVIg) treatment will have a stroke or heart attack.

5 Mar 2009

Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment

5 Mar 2009

Aerovance starts trial of Aerovant for uncontrolled asthma

Aerovance Inc. has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb clinical trial, AeroTrial(TM), of inhaled dry powder Aerovant in patients with uncontrolled asthma.

3 Mar 2009

B-cell clones as early markers for chronic lymphocytic leukemia

Testing of blood specimens may detect abnormal white blood cells in patients years before the chronic form of lymphocytic leukemia (CLL) develops, according to research published in the current issue of the New England Journal of Medicine.

22 Feb 2009

Study on ustekinumab for treatment of psoriatic arthritis published

A group of patients suffering from potentially debilitating psoriatic arthritis showed significant and prolonged improvement after treatment with ustekinumab, according to data from a randomized, double-blind, placebo-controlled study in patients with moderate to severe psoriatic arthritis (PsA).

11 Feb 2009

New nasal spray vaccine shown to be effective against botulism

A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy .

8 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

Australians warned of rabies outbreak in Bali

The warning comes from the head of the Northern Territory's Centre for Disease Control, Dr. Peter Markey, who says anyone bitten or scratched on the island by an animal should seek medical advice; the warning also applies to people who have been to Bali recently.

14 Dec 2008

Research identifies cell receptor as target for anti-inflammatory immune response

Cell reception. By comparing normal mice (left) with mice that are genetically engineered to lack certain receptors in their spleen (right), scientists have shown SIGNR1 receptors (blue) are required to facilitate an anti-inflammatory action.

28 Nov 2008

Humoral immunity in kidney transplantation

There are more than 76,000 end-stage renal disease patients waiting for one of the 17,000 kidneys transplanted each year, making a host rejection an unacceptable waste.

24 Nov 2008

Strong relationship found between allergies and cancer in environmentally exposed tissues

There may be a silver -- and healthy -- lining to the miserable cloud of allergy symptoms: Sneezing, coughing, tearing and itching just may help prevent cancer -- particularly colon, skin, bladder, mouth, throat, uterus and cervix, lung and gastrointestinal tract cancer, according to a new Cornell study.

12 Nov 2008

Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid

Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.

10 Nov 2008

FDA grants approval to Talecris Biotherapeutics for Gamunex for neurological disorder CIDP

Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a debilitating neurological disorder that results in muscle weakness and fatigue, which can lead to severe impairment of motor skills.

15 Sep 2008

FDA approves Gamunex for chronic inflammatory demyelinating polyneuropathy

The U.S. Food and Drug Administration has announced that it has approved an immune globulin product called Gamunex for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms.

14 Sep 2008

FDA authorizes INDA for recombinant human C1 inhibitor in kidney transplantation

Biotech company Pharming Group NV has announced that the US Food and Drug Administration (FDA) has authorized a clinical study with recombinant human C1 inhibitor (rhC1INH) for the treatment of antibody-mediated rejection (AMR) in kidney transplantation. Dr. Hans Sollinger of the University of Wisconsin, Madison will conduct the clinical trial with rhC1INH under an Investigator IND from the FDA.

3 Sep 2008

FDA approves Nplate (romiplostim), first bone marrow stimulator for chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration has approved Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding.

24 Aug 2008

Researchers discover key allergy gene

Together with colleagues from the Department of Dermatology and Allergy and the Center for Allergy and Environment (ZAUM) of the Technische Universitat Munchen, scientists at the Helmholtz Zentrum Munchen have pinpointed a major gene for allergic diseases. The gene was localized using cutting edge technologies for examining the whole human genome at the Helmholtz Zentrum Munchen.